Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9182 |
High Similarity |
NPD4184 |
Clinical (unspecified phase) |
0.9141 |
High Similarity |
NPD6595 |
Phase 3 |
0.8929 |
High Similarity |
NPD8431 |
Approved |
0.8922 |
High Similarity |
NPD6610 |
Clinical (unspecified phase) |
0.8902 |
High Similarity |
NPD6203 |
Clinical (unspecified phase) |
0.8896 |
High Similarity |
NPD5065 |
Approved |
0.878 |
High Similarity |
NPD482 |
Approved |
0.8774 |
High Similarity |
NPD4374 |
Clinical (unspecified phase) |
0.8765 |
High Similarity |
NPD8110 |
Clinical (unspecified phase) |
0.8735 |
High Similarity |
NPD4079 |
Approved |
0.8735 |
High Similarity |
NPD4076 |
Approved |
0.869 |
High Similarity |
NPD2094 |
Phase 2 |
0.869 |
High Similarity |
NPD2095 |
Phase 2 |
0.869 |
High Similarity |
NPD2092 |
Phase 2 |
0.8675 |
High Similarity |
NPD3506 |
Approved |
0.8675 |
High Similarity |
NPD3505 |
Approved |
0.8639 |
High Similarity |
NPD2096 |
Phase 2 |
0.8639 |
High Similarity |
NPD2091 |
Phase 2 |
0.8614 |
High Similarity |
NPD749 |
Clinical (unspecified phase) |
0.858 |
High Similarity |
NPD5728 |
Clinical (unspecified phase) |
0.8563 |
High Similarity |
NPD5575 |
Clinical (unspecified phase) |
0.8537 |
High Similarity |
NPD5069 |
Clinical (unspecified phase) |
0.8523 |
High Similarity |
NPD7948 |
Phase 1 |
0.8497 |
Intermediate Similarity |
NPD786 |
Approved |
0.8452 |
Intermediate Similarity |
NPD2144 |
Approved |
0.8421 |
Intermediate Similarity |
NPD198 |
Clinical (unspecified phase) |
0.8418 |
Intermediate Similarity |
NPD3100 |
Discontinued |
0.8387 |
Intermediate Similarity |
NPD1722 |
Approved |
0.8383 |
Intermediate Similarity |
NPD750 |
Phase 2 |
0.8353 |
Intermediate Similarity |
NPD8464 |
Clinical (unspecified phase) |
0.8333 |
Intermediate Similarity |
NPD4128 |
Approved |
0.8304 |
Intermediate Similarity |
NPD3038 |
Discontinued |
0.8263 |
Intermediate Similarity |
NPD1325 |
Approved |
0.8263 |
Intermediate Similarity |
NPD1326 |
Approved |
0.825 |
Intermediate Similarity |
NPD4462 |
Approved |
0.825 |
Intermediate Similarity |
NPD4463 |
Approved |
0.8214 |
Intermediate Similarity |
NPD5934 |
Clinical (unspecified phase) |
0.8204 |
Intermediate Similarity |
NPD4639 |
Approved |
0.8204 |
Intermediate Similarity |
NPD4638 |
Approved |
0.8204 |
Intermediate Similarity |
NPD4640 |
Approved |
0.8197 |
Intermediate Similarity |
NPD5901 |
Discontinued |
0.8187 |
Intermediate Similarity |
NPD8073 |
Approved |
0.8187 |
Intermediate Similarity |
NPD8386 |
Phase 2 |
0.8176 |
Intermediate Similarity |
NPD6375 |
Clinical (unspecified phase) |
0.8176 |
Intermediate Similarity |
NPD4075 |
Phase 2 |
0.8171 |
Intermediate Similarity |
NPD3961 |
Discontinued |
0.8152 |
Intermediate Similarity |
NPD7958 |
Clinical (unspecified phase) |
0.8152 |
Intermediate Similarity |
NPD7957 |
Phase 1 |
0.8148 |
Intermediate Similarity |
NPD2837 |
Discontinued |
0.8142 |
Intermediate Similarity |
NPD8072 |
Approved |
0.8133 |
Intermediate Similarity |
NPD3323 |
Discontinued |
0.8108 |
Intermediate Similarity |
NPD8493 |
Clinical (unspecified phase) |
0.8065 |
Intermediate Similarity |
NPD7947 |
Clinical (unspecified phase) |
0.8025 |
Intermediate Similarity |
NPD2172 |
Phase 1 |
0.8023 |
Intermediate Similarity |
NPD4181 |
Approved |
0.8022 |
Intermediate Similarity |
NPD7621 |
Clinical (unspecified phase) |
0.8 |
Intermediate Similarity |
NPD5426 |
Phase 3 |
0.7989 |
Intermediate Similarity |
NPD3404 |
Approved |
0.7979 |
Intermediate Similarity |
NPD7998 |
Clinical (unspecified phase) |
0.7966 |
Intermediate Similarity |
NPD3486 |
Clinical (unspecified phase) |
0.7964 |
Intermediate Similarity |
NPD8026 |
Phase 1 |
0.7957 |
Intermediate Similarity |
NPD4862 |
Clinical (unspecified phase) |
0.791 |
Intermediate Similarity |
NPD6217 |
Discontinued |
0.7901 |
Intermediate Similarity |
NPD4702 |
Approved |
0.7901 |
Intermediate Similarity |
NPD7618 |
Phase 3 |
0.7901 |
Intermediate Similarity |
NPD4703 |
Approved |
0.7901 |
Intermediate Similarity |
NPD7619 |
Phase 3 |
0.7895 |
Intermediate Similarity |
NPD8458 |
Clinical (unspecified phase) |
0.7895 |
Intermediate Similarity |
NPD7594 |
Clinical (unspecified phase) |
0.7884 |
Intermediate Similarity |
NPD7825 |
Clinical (unspecified phase) |
0.7875 |
Intermediate Similarity |
NPD4637 |
Clinical (unspecified phase) |
0.787 |
Intermediate Similarity |
NPD5744 |
Clinical (unspecified phase) |
0.7862 |
Intermediate Similarity |
NPD3943 |
Clinical (unspecified phase) |
0.7853 |
Intermediate Similarity |
NPD8488 |
Clinical (unspecified phase) |
0.7845 |
Intermediate Similarity |
NPD1038 |
Approved |
0.7845 |
Intermediate Similarity |
NPD1304 |
Clinical (unspecified phase) |
0.7842 |
Intermediate Similarity |
NPD8013 |
Clinical (unspecified phase) |
0.7842 |
Intermediate Similarity |
NPD7470 |
Discontinued |
0.7812 |
Intermediate Similarity |
NPD8112 |
Clinical (unspecified phase) |
0.7807 |
Intermediate Similarity |
NPD8272 |
Phase 2 |
0.7802 |
Intermediate Similarity |
NPD7944 |
Discontinued |
0.7798 |
Intermediate Similarity |
NPD1403 |
Approved |
0.7798 |
Intermediate Similarity |
NPD1404 |
Approved |
0.7791 |
Intermediate Similarity |
NPD3609 |
Approved |
0.7791 |
Intermediate Similarity |
NPD3610 |
Approved |
0.7789 |
Intermediate Similarity |
NPD7809 |
Clinical (unspecified phase) |
0.7784 |
Intermediate Similarity |
NPD484 |
Approved |
0.7778 |
Intermediate Similarity |
NPD2185 |
Clinical (unspecified phase) |
0.7778 |
Intermediate Similarity |
NPD2640 |
Approved |
0.7778 |
Intermediate Similarity |
NPD5021 |
Discontinued |
0.7778 |
Intermediate Similarity |
NPD2641 |
Approved |
0.7751 |
Intermediate Similarity |
NPD1853 |
Clinical (unspecified phase) |
0.7735 |
Intermediate Similarity |
NPD6180 |
Clinical (unspecified phase) |
0.7732 |
Intermediate Similarity |
NPD8406 |
Clinical (unspecified phase) |
0.7727 |
Intermediate Similarity |
NPD6277 |
Clinical (unspecified phase) |
0.7725 |
Intermediate Similarity |
NPD6838 |
Clinical (unspecified phase) |
0.7719 |
Intermediate Similarity |
NPD2639 |
Approved |
0.7719 |
Intermediate Similarity |
NPD2642 |
Approved |
0.7716 |
Intermediate Similarity |
NPD3813 |
Approved |
0.7716 |
Intermediate Similarity |
NPD5254 |
Discontinued |
0.7701 |
Intermediate Similarity |
NPD2928 |
Phase 2 |
0.7692 |
Intermediate Similarity |
NPD8405 |
Clinical (unspecified phase) |
0.768 |
Intermediate Similarity |
NPD5612 |
Discontinued |
0.7674 |
Intermediate Similarity |
NPD5862 |
Discovery |
0.7674 |
Intermediate Similarity |
NPD4779 |
Clinical (unspecified phase) |
0.7667 |
Intermediate Similarity |
NPD6141 |
Clinical (unspecified phase) |
0.7667 |
Intermediate Similarity |
NPD5590 |
Clinical (unspecified phase) |
0.7651 |
Intermediate Similarity |
NPD6158 |
Phase 2 |
0.7651 |
Intermediate Similarity |
NPD6476 |
Clinical (unspecified phase) |
0.765 |
Intermediate Similarity |
NPD802 |
Phase 2 |
0.7647 |
Intermediate Similarity |
NPD972 |
Clinical (unspecified phase) |
0.764 |
Intermediate Similarity |
NPD5106 |
Approved |
0.764 |
Intermediate Similarity |
NPD5105 |
Approved |
0.7622 |
Intermediate Similarity |
NPD6148 |
Clinical (unspecified phase) |
0.7617 |
Intermediate Similarity |
NPD8093 |
Discontinued |
0.7611 |
Intermediate Similarity |
NPD4426 |
Clinical (unspecified phase) |
0.7598 |
Intermediate Similarity |
NPD6178 |
Phase 3 |
0.7598 |
Intermediate Similarity |
NPD3607 |
Clinical (unspecified phase) |
0.7595 |
Intermediate Similarity |
NPD3385 |
Approved |
0.7593 |
Intermediate Similarity |
NPD1592 |
Phase 3 |
0.759 |
Intermediate Similarity |
NPD6803 |
Clinical (unspecified phase) |
0.7582 |
Intermediate Similarity |
NPD4499 |
Approved |
0.7576 |
Intermediate Similarity |
NPD1661 |
Suspended |
0.7576 |
Intermediate Similarity |
NPD4547 |
Phase 3 |
0.7568 |
Intermediate Similarity |
NPD7818 |
Clinical (unspecified phase) |
0.7557 |
Intermediate Similarity |
NPD5100 |
Phase 3 |
0.7552 |
Intermediate Similarity |
NPD2125 |
Clinical (unspecified phase) |
0.7548 |
Intermediate Similarity |
NPD992 |
Clinical (unspecified phase) |
0.7548 |
Intermediate Similarity |
NPD991 |
Phase 2 |
0.7543 |
Intermediate Similarity |
NPD4112 |
Clinical (unspecified phase) |
0.7529 |
Intermediate Similarity |
NPD5255 |
Approved |
0.7527 |
Intermediate Similarity |
NPD6664 |
Approved |
0.7515 |
Intermediate Similarity |
NPD1683 |
Approved |
0.7514 |
Intermediate Similarity |
NPD706 |
Phase 1 |
0.7514 |
Intermediate Similarity |
NPD8122 |
Approved |
0.7514 |
Intermediate Similarity |
NPD8123 |
Approved |
0.75 |
Intermediate Similarity |
NPD5140 |
Approved |
0.75 |
Intermediate Similarity |
NPD5138 |
Approved |
0.7487 |
Intermediate Similarity |
NPD8094 |
Discontinued |
0.7486 |
Intermediate Similarity |
NPD5117 |
Phase 2 |
0.7486 |
Intermediate Similarity |
NPD6281 |
Approved |
0.7471 |
Intermediate Similarity |
NPD4326 |
Phase 2 |
0.746 |
Intermediate Similarity |
NPD4511 |
Phase 1 |
0.7458 |
Intermediate Similarity |
NPD2382 |
Approved |
0.7458 |
Intermediate Similarity |
NPD2381 |
Approved |
0.7458 |
Intermediate Similarity |
NPD2380 |
Approved |
0.7453 |
Intermediate Similarity |
NPD1262 |
Discovery |
0.7448 |
Intermediate Similarity |
NPD8410 |
Clinical (unspecified phase) |
0.7447 |
Intermediate Similarity |
NPD3814 |
Phase 1 |
0.7447 |
Intermediate Similarity |
NPD3825 |
Phase 3 |
0.744 |
Intermediate Similarity |
NPD3262 |
Approved |
0.744 |
Intermediate Similarity |
NPD2882 |
Phase 1 |
0.7439 |
Intermediate Similarity |
NPD3717 |
Discontinued |
0.7439 |
Intermediate Similarity |
NPD2006 |
Phase 2 |
0.7436 |
Intermediate Similarity |
NPD3330 |
Phase 1 |
0.743 |
Intermediate Similarity |
NPD6452 |
Discontinued |
0.7425 |
Intermediate Similarity |
NPD2430 |
Phase 2 |
0.7412 |
Intermediate Similarity |
NPD2748 |
Clinical (unspecified phase) |
0.741 |
Intermediate Similarity |
NPD7469 |
Discontinued |
0.7407 |
Intermediate Similarity |
NPD8248 |
Clinical (unspecified phase) |
0.7407 |
Intermediate Similarity |
NPD4601 |
Approved |
0.7407 |
Intermediate Similarity |
NPD4600 |
Approved |
0.7405 |
Intermediate Similarity |
NPD3475 |
Approved |
0.7405 |
Intermediate Similarity |
NPD4615 |
Phase 2 |
0.7405 |
Intermediate Similarity |
NPD3476 |
Approved |
0.7396 |
Intermediate Similarity |
NPD2012 |
Clinical (unspecified phase) |
0.7394 |
Intermediate Similarity |
NPD3230 |
Clinical (unspecified phase) |
0.7386 |
Intermediate Similarity |
NPD3117 |
Approved |
0.7386 |
Intermediate Similarity |
NPD3116 |
Approved |
0.7385 |
Intermediate Similarity |
NPD5066 |
Phase 2 |
0.7385 |
Intermediate Similarity |
NPD5067 |
Phase 2 |
0.738 |
Intermediate Similarity |
NPD6449 |
Clinical (unspecified phase) |
0.7376 |
Intermediate Similarity |
NPD7271 |
Approved |
0.7374 |
Intermediate Similarity |
NPD5818 |
Discontinued |
0.7374 |
Intermediate Similarity |
NPD7823 |
Clinical (unspecified phase) |
0.7371 |
Intermediate Similarity |
NPD2844 |
Phase 3 |
0.7363 |
Intermediate Similarity |
NPD5555 |
Phase 1 |
0.7356 |
Intermediate Similarity |
NPD2719 |
Clinical (unspecified phase) |
0.7356 |
Intermediate Similarity |
NPD2720 |
Phase 1 |
0.7356 |
Intermediate Similarity |
NPD4550 |
Clinical (unspecified phase) |
0.7354 |
Intermediate Similarity |
NPD6999 |
Discontinued |
0.7354 |
Intermediate Similarity |
NPD7000 |
Clinical (unspecified phase) |
0.7351 |
Intermediate Similarity |
NPD6630 |
Clinical (unspecified phase) |
0.7351 |
Intermediate Similarity |
NPD5913 |
Phase 3 |
0.7351 |
Intermediate Similarity |
NPD5912 |
Clinical (unspecified phase) |
0.735 |
Intermediate Similarity |
NPD6242 |
Discontinued |
0.7348 |
Intermediate Similarity |
NPD2391 |
Clinical (unspecified phase) |
0.7342 |
Intermediate Similarity |
NPD3654 |
Approved |
0.7341 |
Intermediate Similarity |
NPD2385 |
Clinical (unspecified phase) |
0.7333 |
Intermediate Similarity |
NPD2007 |
Clinical (unspecified phase) |
0.733 |
Intermediate Similarity |
NPD5436 |
Phase 1 |
0.733 |
Intermediate Similarity |
NPD5721 |
Clinical (unspecified phase) |
0.7325 |
Intermediate Similarity |
NPD2119 |
Approved |
0.7325 |
Intermediate Similarity |
NPD2118 |
Approved |
0.731 |
Intermediate Similarity |
NPD276 |
Clinical (unspecified phase) |
0.731 |
Intermediate Similarity |
NPD2580 |
Discontinued |
0.7304 |
Intermediate Similarity |
NPD7731 |
Approved |
0.7304 |
Intermediate Similarity |
NPD7730 |
Approved |
0.7303 |
Intermediate Similarity |
NPD6492 |
Phase 2 |
0.7301
|
Intermediate Similarity |
NPD2896 |
Discontinued |